0001689813-19-000071.txt : 20191025
0001689813-19-000071.hdr.sgml : 20191025
20191025203951
ACCESSION NUMBER: 0001689813-19-000071
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191018
FILED AS OF DATE: 20191025
DATE AS OF CHANGE: 20191025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stock Elyse
CENTRAL INDEX KEY: 0001785732
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38080
FILM NUMBER: 191171014
BUSINESS ADDRESS:
BUSINESS PHONE: (203) 404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd.
CENTRAL INDEX KEY: 0001689813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
wf-form4_157205036147621.xml
FORM 4
X0306
4
2019-10-18
0
0001689813
Biohaven Pharmaceutical Holding Co Ltd.
BHVN
0001785732
Stock Elyse
C/O BIOHAVEN PHARMACEUTICALS, INC., 215
CHURCH STREET
NEW HAVEN
CT
06510
0
1
0
0
Chief Medical Officer
Common Shares
2019-10-18
4
M
0
17700
10.82
A
17700
D
Common Shares
2019-10-18
4
S
0
17700
45.0706
D
0
D
Employee Stock Option (Right to Buy)
10.82
2019-10-18
4
M
0
17700
0
D
2027-04-05
Common Shares
17700.0
18500
D
These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 - $45.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The option, representing a right to purchase a total of 37,000 shares, became exercisable as to 18,500 shares on and prior to April 6, 2019 and becomes exercisable as to the remaining 18,500 shares on April 6, 2020, subject to the reporting person's continued service as of such date. The Reporting Person previously exercised the option with respect to 800 shares on October 15, 2019.
/s/ Jim Engelhart, Attorney-in-fact
2019-10-25